OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - EDWARDS LIFESCIENCES | Delayed Deutsche Boerse AG 10:09:28 2024-05-13 am EDT | ||
| 2.6 EUR | -1.52% |
|
| Current month | +6.45% | ||
| 1 month | -15.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 2.6 | -1.52% | 0 |
| 24-05-10 | 2.64 | -2.94% | 0 |
| 24-05-09 | 2.72 | +9.24% | 0 |
| 24-05-08 | 2.49 | -3.49% | 0 |
| 24-05-07 | 2.58 | +3.61% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 10:09 am EDT
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SV10N2 |
| ISIN | DE000SV10N22 |
| Date issued | 2023-03-13 |
| Strike | 58.31 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.78 € |
|---|---|
| Lowest since issue | 0.51 € |
| Spread | 0.01 € |
| Spread % | 0.38% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
86.72
USD
Average target price
95.27
USD
Spread / Average Target
+9.86%
- Stock Market
- Certificates
- Certificat
